Preferred Label : Genetic Screening;

NCIt definition : Testing to determine if there is a predisposition or indication of a possible genetic or a chromosomal abnormality.;

Alternative definition : NCI-GLOSS: Genetic testing designed to identify individuals in a given population who are at higher risk of having or developing a particular disorder, or carrying a gene for a particular disorder.;

Codes from synonyms : CDR0000460215;

Details


Main resources

You can consult :


https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/depistage-du-diabete-de-type-2-et-evaluation-du-risque-cardiovasculaire.html
2024
Canada
technical report
Cardiovascular Risk
Last Screening
Eligibility Determination
Genetic Screening
Trial Screening
Health Risk Assessment
Murine Cardiovascular System
Type 2 Diabetes Mellitus
Site Screening
Cancer Screening
mass screening
diabetes non-insulin dependent
screening for diabetes
screening
risk assessment
diabetes mellitus, type 2
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Screening Study
Cardiovascular
Cardiovascular System
cardiovascular risk
Substance Screening

---
https://www.cfp.ca/content/70/7-8/e89
2024
Canada
journal article
Screening Study
Approach
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
infectious disease, nos
sexually transmitted diseases
Eligibility Determination
men
Last Screening
Menogaril
Multiple Endocrine Neoplasia
mass screening
Genetic Screening
coitus
Infections
Sexually Transmitted Disorder
Site Screening
Sexual Intercourse
Substance Screening
Man
screening
Trial Screening
sexual intercourse, nos
Cancer Screening
Mende Language
ELL wt Allele

---
http://www.eaclf.org/docs/TestADNlc-Notice_final.pdf
2024
France
patient education handout
Last Screening
information dissemination
pregnancy, nos
Destination
Circulating Cell-Free DNA
emigration and immigration
Informative
mass screening
Screening Study
Cytogenetic Abnormality
Substance Screening
Chromosome Disorder
Cell-Free DNA Blood Collection Tube
dna analysis, nos
DNA Analysis
chromosomal disease, nos
cfDNA Mutation
Informed
Pregnant People
DNA
Gravida
Genetic Screening
Cell-Free Nucleic Acids
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
chromosome analysis, nos
Cancer Screening
Trial Screening
Eligibility Determination
Site Screening
No Information Available
screening
chromosomes
chromosome aberrations
Oprelvekin

---
http://beh.santepubliquefrance.fr/beh/2024/14/2024_14_1.html
2024
France
journal article
prophylactic treatment, nos
Socializing
Preventive Intervention
Eligibility Determination
Central Nervous System Prophylaxis
TRPM6 wt Allele
Social
Last Screening
Multiple Endocrine Neoplasia
PITRM1 wt Allele
mass screening
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Man
Mende Language
Screening Study
Reside
Cancer Screening
Pre-Exposure Prophylaxis
socialism
Exposure
Sexual Intercourse
Substance Screening
sexual exposure
geography
screening
Genetic Screening
Exposure Domain
Island
CHFR Gene
france
Isoleucine
coitus
men
Geography-Based Enrollment
sexual intercourse, nos
Site Screening
geographer
Isoleucine Measurement
french
Trial Screening
Prevention
Ivor Lewis Esophagectomy
ELL wt Allele
Geographic
Menogaril
Preparation
paris

---
https://www.pedia-univ.fr/deuxieme-cycle/referentiel/croissance-developpement/depistages-lenfant
2024
France
educational course
Screening Study
mass screening
Genetic Screening
Last Screening
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Child Relation
child
Trial Screening
Site Screening
Child Individual
child, nos
Cancer Screening
Substance Screening
Eligibility Determination
screening

---
https://www.sfdiabete.org/sites/www.sfdiabete.org/files/files/ressources/depistage_prise_en_charge_dt1.pdf
2024
France
practice guideline
Algeria
Last Screening
French Language
Position
Eligibility Determination
Gene Physical Location
Twelve
Substance Screening
Preclinical
french
consultants
Cancer Screening
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Charge
Phase
patient care management
Site Screening
Type 1 Diabetes Mellitus
screening
French Catheter Gauge
Life Stage
mass screening
Trial Screening
CDISC SDTM Body Position Terminology
diabetes mellitus, type 1
france
screening for diabetes
Genetic Screening
Screening Study

---
https://jefaismondepistage.e-cancer.fr/
2024
France
popular works
Screening Study
Eligibility Determination
Substance Screening
screening
Cancer Screening
Genetic Screening
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Trial Screening
Site Screening
mass screening
Last Screening

---
https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2024-50/numero-6-juin-2024/depistage-sras-cov-2-infection-taux-vaccination-travailleurs-essentiels-non-soignants.html
2024
Canada
journal article
ATRX Mutation Analysis Was Not Performed
vaccination
First Degree Family History of Primary Brain Tumor Negative
Tumor Progression Absent After Initial Treatment
Has No Sibling
Chemotherapy Was Not Administered as an Additional Treatment for a New Tumor Event
Targeted Molecular Therapy Was Not Administered as an Additional Treatment for a New Tumor Event
Adjuvant I-131 Therapy Negative
No History of Non-Cardiac Surgery
Adjuvant Post-operative Immunological Therapy Was Not Administered
Additional Molecular Studies Were Not Performed
Chemotherapy Not Received
Infection
ROS1 Rearrangement Analysis Was Not Performed
Genetic Screening
Intercurrent Illness is Absent at Onset of Chief Complaint
Severe Acute Respiratory Syndrome
Additional Surgery for New Metastatic Tumor Event Was Not Performed
Norway
No History of Gestational Complication
Preoperative IV Antiemetics were not Administered
Other Preoperative IV Medications were not Administered
No Response to Intervention for Kawasaki Disease
Radiation Was Not Administered as an Additional Treatment for a New Tumor Event
mass screening
Regular Smokeless Tobacco Use for Six Weeks or More Negative
Nitric Oxide Measurement
History of Medical Treatment Absent
EGFR Amplification Analysis Was Not Performed
Peripheral Blood Immunophenotyping and Cytochemistry Were Not Performed
Any Metastatic Diagnosis Absent
Characteristic
Preoperative IV Antacids were not Administered
Minor Criteria for Rheumatic Heart Disease Not Present
Lymph Node Dissection Was Not Performed
PTEN Mutation Analysis Was Not Performed
preventive immunization/medication
Fluorescence In Situ Hybridization Was Not Performed
Preoperative IV Opiates were not Administered
Neither Case or Control Status
ERBB2 Mutation Analysis Was Not Performed
SARS Coronavirus
Routine Cytogenetics Were not Completed
SDH Complex Mutation Analysis Was Not Performed
Severe acute respiratory syndrome-related coronavirus
screening
First Degree Family History Cancer Negative
Trial Screening
Caffeine Not Routinely Consumed
Radiation History Negative
Evidence of Disease Absent after Completion of Therapy
ATRX Gene Mutation Negative
Hormone Therapy Was Not Administered as an Additional Treatment for a New Tumor Event
Adjuvant Post-operative Targeted Molecular Therapy Was Not Administered
TP53 Mutation Analysis Was Not Performed
vaccination
No History of Congenital Heart Disease
Additional Immunohistochemistry Was Not Performed
BRAF Rearrangement Analysis Was Not Performed
Screening Study
Chief Complaint Not Caused by Trauma
Multiple Known Primary Tumors Absent at Initial Melanoma Diagnosis
Radiation Therapy Not Received
Site Screening
Documentation Absent
Patient was Not Previously Evaluated for Current Chief Complaint
BRAF Mutation Analysis Was Not Performed
Subsequent Known Primary Melanoma(s) Not Found During the Follow-Up
MGMT Promoter Methylation Testing Was Not Performed
Therapeutic Ionizing Radiation to Head History Absent
1p/19q Deletion Analysis Was Not Performed
Intervention Not Given for Kawasaki Disease
Preoperative IV Sedation was Not Administered
Chief Complaint was Not Witnessed
Substance Screening
NF1 Mutation Analysis Was Not Performed
Additional Surgery for New Loco-Regional Tumor Event Was Not Performed
Unemployed
Adjuvant Post-operative Radiation Therapy Was Not Administered
Regional Anesthesia was not Administered
Adjuvant Post-operative Chemotherapy Was Not Administered
New Disease is not Multifocal
MET Mutation Analysis Was Not Performed
Interferon Gamma Treatment was not Administered 90 Days Prior to Specimen Resection
Paraneoplastic Syndrome is Not Present
RET Rearrangement Analysis Was Not Performed
No Known History of Alcohol Use
EGFR Gene Amplification Negative
Local Anesthesia Agents were not Administered
IDH Family Wildtype
Family History of Stomach Cancer Absent
IDH Family Mutation Analysis Was Not Performed
infectious disease, nos
Another Form of Birth Control was not Used
Cancer History Absent
History of Colorectal Cancer Negative
EGFR Mutation Analysis Was Not Performed
KRAS Mutation Analysis Was Not Performed
PDGFRA Mutation Analysis Was Not Performed
First Degree Family History Thyroid Cancer Negative
No History of Rheumatic Fever
No History of Myopathy
Vaccination
10q23/PTEN Locus Deletion Analysis Was Not Performed
Last Screening
Use of Smokeless Tobacco at Time of Diagnosis Negative
Adverse Event Associated with Infection
Neither
No History of Neonatal Complication
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
caregivers
Eligibility Determination
New Tumor Event After Initial Treatment Absent
Not Lost to Follow-Up
PTEN Gene Mutation Negative
has provider
Interferon Gamma Treatment was not Administered Prior to Specimen Resection
Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Not Performed
vaccination, nos
Physician Diagnosed Diabetes Absent
NON Mouse
Immunotherapy Was Not Administered as an Additional Treatment for a New Tumor Event
NRAS Mutation Analysis Was Not Performed
Additional Surgery for New Tumor Event Absent
No Known History of Illicit Drug Use
Adjuvant Post-operative Pharmaceutical Therapy Was Not Administered
ALK Rearrangement Analysis Was Not Performed
IV Anesthesia was not Administered
Cancer Screening
Medication Not Taken
Patient was not Postmenopausal with no Prior Oophorectomy
Nitric Oxide
No History of Other Muscular Dystrophy or Glycogen Storage Disorder
KIT Mutation Analysis Was Not Performed
Chemical/Occupational Exposure Absent
Tumor Reoccurrence Absent After Initial Treatment
Negation
No History of Kawasaki Disease
Hypertension Absent

---
https://www.cochrane.org/fr/CD011060/NEONATAL_depistage-transcutane-de-la-bilirubine-dans-lictere-du-nouveau-ne
2024
United Kingdom
review of literature
french abstract
newborn, nos
Cancer Screening
Site Screening
bilirubin, nos
Jaundice
Last Screening
Genetic Screening
Screening Study
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Newar Language
Eligibility Determination
Trial Screening
Substance Screening
jaundice
Icteric Index
screening
jaundice
Bilirubin
New Lesion Identification
infant, newborn
jaundice, nos
neonatal screening
jaundice, neonatal
bilirubin
ITGAE Gene

---
https://www.rp2s.fr/wp-content/uploads/2024_Diabete-gestationnel_VDef.pdf
https://www.rp2s.fr/wp-content/uploads/2024_DG_Annexe1_Depistage.pdf
https://www.rp2s.fr/wp-content/uploads/2024_DG_Annexe2_Grossesse.pdf
https://www.rp2s.fr/wp-content/uploads/2024_DG_Annexe3_Accouchement.pdf
2024
France
guideline
Cancer Screening
screening
patient care management
Gestational Diabetes
mass screening
Substance Screening
Genetic Screening
Last Screening
Site Screening
Screening Study
diabetes, gestational
Trial Screening
screening for diabetes
Charge
Eligibility Determination
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening

---
http://beh.santepubliquefrance.fr/beh/2024/6-7/2024_6-7_3.html
2024
France
journal article
Substance Screening
Screening Study
french
Organization
Tuberculosis
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Relocation
france
Genetic Screening
Other Agency or Organization
mass screening
organization
Cancer Screening
Trial Screening
CHFR Gene
ukraine
tuberculosis
Site Screening
Replacement
Checkup
screening
tuberculosis, nos
Balance Sheet
Last Screening
tuberculosis
Reposition
Eligibility Determination
Organization Name

---
https://beh.santepubliquefrance.fr/beh/2024/6-7/2024_6-7_3.html
2024
France
journal article
Eligibility Determination
CHFR Gene
screening
Replacement
Relocation
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
ukraine
Other Agency or Organization
Balance Sheet
Screening Study
tuberculosis
organization
tuberculosis, nos
france
Tuberculosis
Checkup
Organization
tuberculosis
Cancer Screening
Site Screening
Trial Screening
Reposition
mass screening
Substance Screening
Last Screening
Genetic Screening
Organization Name
french

---
https://iris.who.int/handle/10665/376140
2024
Switzerland
scientific and technical information
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Diastolic Blood Pressure
Diabetes Mellitus
Cancer Screening
Antigua and Barbuda
Trial Screening
screening
Engaged
Eligibility Determination
screening for diabetes
Substance Screening
Improved
serbia
quality improvement
Enhance
Screening Study
registries
diabetes mellitus
Involvement
prejudice
Twenty Eight
Site Screening
Notification
mass screening
Last Screening
Have Diabetes
Genetic Screening
Propofol Infusion Syndrome
November

---
https://www.cochrane.org/fr/CD001431/COMMUN_les-outils-daide-la-decision-pour-les-patients-confrontes-des-decisions-relatives-un-traitement
2024
United Kingdom
review of literature
french abstract
tool, nos
Substance Screening
Decision Aid
Tool
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Site Screening
Screening Study
has patient
decision support techniques
Last Screening
mass screening
screening
operations research
Medically Treated Reflux
Genetic Screening
decision aids
Patient
Cancer Screening
A^y/a
patients
Eligibility Determination
Trial Screening
Scientific Equipment

---
https://www.cmg.fr/wp-content/uploads/2024/02/Le-depistage-cutane-CMG2024.pdf
2024
France
patient education handout
Substance Screening
Trial Screening
Cancer Screening
skin, nos
Screening Study
Site Screening
Last Screening
mass screening
screening
Cutaneous
Genetic Screening
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Eligibility Determination
Cutaneous Route of Administration

---
https://publications.msss.gouv.qc.ca/msss/document-001746/
2024
Canada
patient education handout
deafness
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Eligibility Determination
Scheduled
infant, newborn
screening
Program
Newar Language
Screening Study
NES Gene
Cancer Screening
New Lesion Identification
LGI1 wt Allele
deafness
Substance Screening
neonatal screening
deafness, nos
Trial Screening
Deafness
Site Screening
Genetic Screening
Schedule
newborn, nos
ANGPTL4 wt Allele
Last Screening

---
https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=1367
2024
France
public health guidelines
mass screening
Trial Screening
Pregnancy
Eligibility Determination
pregnancy
Last Screening
pregnancy complications, infectious
Substance Screening
cytomegalovirus infections
Cytomegaloviral Infection
Cancer Screening
Genetic Screening
Screening Study
Site Screening
cytomegalovirus infection, nos
pregnancy, nos
Pregnant
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening

---
https://www.has-sante.fr/jcms/p_3535602/fr/evaluation-de-la-pertinence-d-un-depistage-systematique-de-l-infection-a-cytomegalovirus-cmv-au-cours-de-la-grossesse-feuille-de-route
2024
France
public health guidelines
Assessment
Site Screening
Assessment
pregnancy, nos
mass screening
Genetic Screening
pregnancy
Protocol Treatment Course
Evaluation
Last Screening
Cancer Screening
cytomegalovirus infection, nos
Trial Screening
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Screening Study
Pregnancy
Cytomegalovirus
Execution
Pregnant
cytomegalovirus infections
Physical Examination
Eligibility Determination
Substance Screening
evaluation studies as topic

---
https://www.canada.ca/fr/sante-publique/services/vih-sida/guide-depistage-diagnostic-infection-vih.html
2024
Canada
guideline
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Substance Screening
HIV Infection
viruses
hiv infections
Cancer Screening
no diagnosis
mass screening
HIV Infection Diagnosis
human immunodeficiency virus infection, nos
HIV
screening
Screening Study
Last Screening
humans
Guide Device
Human Immunodeficiency Virus
Eligibility Determination
human immunodeficiency virus, nos
Handbook
Genetic Screening
Date of Diagnosis
Diagnosis Study
Trial Screening
Site Screening
Diagnosis Code

---
https://dumas.ccsd.cnrs.fr/dumas-04413875
2023
France
dissertations, academic
depression, postpartum
Binding
Woman
tool use behavior
female
perinatal state, nos
child
reactive attachment disorder
Fastener Device
Site Screening
Fix
women
Female Phenotype
Last Screening
Childhood Depression
mother, nos
Scientific Equipment
depressive disorder
mass screening
Wife
child, nos
Cancer Screening
depression
Substance Screening
Use
Perinatal Depression
Tool
Screening Study
Genetic Screening
Trial Screening
psychometrics
Phenylmercuric Acetate
Oman
screening
tool, nos
Eligibility Determination
depression, nos
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening

---
https://dumas.ccsd.cnrs.fr/dumas-04171805
2023
France
dissertations, academic
Tool
evaluation studies as topic
Substance Screening
Assessment
Biomedicine
general practice
hypertension
pediatrics
Screening Study
Pediatricians
Hypertension
screening
Trial Screening
Cancer Screening
Scientific Equipment
tool, nos
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
pediatrician
Physical Examination
Site Screening
Assessment
hypertensive disease, nos
Eligibility Determination
Family Practice
Evaluation
Pediatrics
Genetic Screening
mass screening
Last Screening

---
https://n2t.net/ark:/47881/m600023w
2023
France
dissertations, academic
Family Practice
Cancer Screening
Development Batch
tool, nos
Maturation
patient care management
general practice
Biomedicine
mass screening
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Substance Screening
Last Screening
Charge
Genetic Screening
screening
Development Lot
Screening Study
Eligibility Determination
teaching
Trial Screening
Tool
Scientific Equipment
Site Screening
Psychological Trauma
pedagogy

---
https://www.enfant-encyclopedie.com/anxiete-et-depression/selon-experts/depistage-et-evaluation-de-lanxiete-et-de-la-depression-pendant
2023
Canada
scientific and technical information
Assessment
Worry
Anxiety
Evaluation
Site Screening
Last Screening
anxiety disorder of childhood, nos
depression
depression, nos
Substance Screening
Feel Anxious
Eligibility Determination
Anxiety Disorder
depressive disorder
Screening Study
evaluation studies as topic
screening
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
anxiety
mass screening
Early Childhood
Anxiety, CTCAE 3.0
Physical Examination
Trial Screening
Cancer Screening
Childhood Depression
Genetic Screening
Assessment

---
https://www.paediatrieschweiz.ch/fr/depistage-de-la-dysplasie-developpementale-de-la-hanche-en-suisse/
2023
Switzerland
journal article
Swiss Mice (sdc)
RPL29 wt Allele
Oral Health Impact Profile
Developmental Dysplasia of the Hip
Cancer Screening
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Genetic Screening
Trial Screening
Ischium
dysplasia, nos
Hip Joint
screening
swiss
2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine
GJB2 wt Allele
Zinc Finger FYVE Domain-Containing Protein 9
SDHB wt Allele
E3 Ubiquitin-Protein Ligase RNF31
Screening Study
ZFYVE9 wt Allele
Last Screening
Hsc70-Interacting Protein
ST13 wt Allele
Eligibility Determination
Swiss
Hedgehog-Interacting Protein
REG3A wt Allele
60S Ribosomal Protein L29
Hypoxic Ischemic Encephalopathy
switzerland
Site Screening
Substance Screening
Dysplasia
HHIP wt Allele
Urticaria
Hip
Health Information Exchange
RNF31 wt Allele
mass screening

---
http://thesesante.ups-tlse.fr/4447/
2023
France
dissertations, academic
Agreement Score 4
Cancer Screening
Trial Screening
Illness Intrusiveness Rating 4
Autonomic Nervous System
general practice
Current Reformed Smoker Within Past 15 Years
Thought Score 4
Upset Score 4
Substance Screening
Child Relation
Clinical Status Ordinal Scale Outcome 4
Afghanistan
Site Screening
Intensity and Distress 4
child, nos
Genetic Screening
screening
Gleason Grade Group 4
Severity of Symptom Score 4
pediatrics
Physical Examination
child
mass screening
Child Individual
Screening Study
Primary Care Provider
Four
Eligibility Determination
Symptoms Extent Score 4
ECOG Performance Status 4
Last Screening
general practitioners
Phase IV Trial
Fear Score 4
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening

---
https://dumas.ccsd.cnrs.fr/dumas-04245064
2023
France
dissertations, academic
Going Well
general practitioners
Eligibility Determination
Last Screening
Screening Study
Trial Screening
Liver Specific Alkaline Phosphatase Measurement
Prevention
Charge
Autoimmune Lymphoproliferative Syndrome
Prevention Study
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
mass screening
Autonomic Nervous System
Cyberbullying
Genetic Screening
Cancer Screening
screening
patient care management
Substance Screening
Clinical Trial Registry Identifier
Preventive Intervention
Site Screening

---
https://dumas.ccsd.cnrs.fr/dumas-04239347
2023
France
dissertations, academic
rheumatic diseases
Rheumatism
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Screening Study
Review
comorbidity
Site Screening
GDC Comorbidity Terminology
Patient
Genetic Screening
Eligibility Determination
Last Screening
physicians
Substance Screening
mass screening
Cancer Screening
patients
Medication
rheumatism, nos
Inflammatory
Systematic Review
Implementation
has patient
Trial Screening
rheumatic fever

---
https://dumas.ccsd.cnrs.fr/dumas-04208921
2023
France
dissertations, academic
Violence
violence
primary health care
Scientific Equipment
Country Code
Last Screening
File Validated
Woman
Tool
Netherlands
Eligibility Determination
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
women
nursing
principal
Substance Screening
Tumor Identifier Evaluator Identifier
Cancer Screening
Going Well
screening
Primary Care
Validation
primary health care
Organisation for Economic Co-Operation and Development
Validation Batch
tool, nos
Trial Screening
Screening Study
Genetic Screening
CDISC SEND Country Terminology
mass screening
Site Screening

---
https://www.srlf.org/article/thromboses-veineuses-liees-aux-catheters-patients-soins-intensifs-reanimation-interet-du
2023
France
critical appraisal or critical reading
Venous Thrombosis
Eligibility Determination
Last Screening
Resuscitation
critical care
Catheterization
Cancer Screening
has patient
Screening Study
What Month is it
catheterization of vein, nos
Reasoning
Substance Screening
patient care
Trial Screening
venous thrombosis
Intensive Care Stay Required
screening
intensive care
Genetic Screening
mass screening
Patient Care
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
venous thrombosis, nos
catheters
Site Screening

---
https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=1348
2023
France
scientific and technical information
screening
Biological
syphilis
biology
Blood
Screening Study
blood donor, nos
Biological or Textual Reference to Actual Test or Parameter
biology
Genetic Screening
Murine Blood
Eligibility Determination
Cancer Screening
Trial Screening
Syphilis
blood donors
mass screening
Site Screening
Blood Sample
Biological Son
Biological Agent
Substance Screening
syphilis, nos
Last Screening
Biological Challenge Agent
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Biology

---
https://www.cmg.fr/wp-content/uploads/2023/03/CMG-Prevention-et-depistage-en-medecine-generale.pdf
2023
France
scientific and technical information
health personnel
Genetic Screening
preventive medicine
Splayed
Preventive Medicine
Substance Screening
Trial Screening
Last Screening
Eligibility Determination
screening
Primary Care Provider
mass screening
Cancer Screening
Site Screening
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Screening Study
general practice
general practitioners

---
https://www.sf2h.net/k-stock/data/uploads/2023/01/Avis-SFM-Depistage-des-MO-en-NN-2023.pdf
2023
France
guideline
organ part
Trial Screening
Cancer Screening
Eligibility Determination
Neither Agree or Disagree
Genetic Screening
Organism
mass screening
neonatology
judgment
Patient
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Million Organisms
Site Screening
Best Practice
Organisms Category
neonatologist
Last Screening
screening
Micro
organizations
Microscopic
Stage 0 Squamous Cell Carcinoma
best practices
has patient
patients
Relative Value
microscopy
Screening Study
Substance Screening

---
https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2023-49/issue-9-september-2023/ccdrv49i09a04af-fra.pdf
2023
Canada
scientific and technical information
Genetic Screening
Last Screening
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
gonorrhea
pregnancy
Substance Screening
chlamydia, nos
Pregnancy
gonorrhea, nos
Cancer Screening
Site Screening
health planning guidelines
Gonorrhea
chlamydia
Working Kelpie
Screening Study
Eligibility Determination
screening
canada
Chlamydia
pregnancy, nos
Chlamydial Infection
Chlamydia Measurement
Trial Screening
mass screening
Pregnant

---
https://nuxeo.u-bourgogne.fr/nuxeo/site/esupversions/838246d1-13f5-45db-9ec7-f7c7599fd7c9
2023
France
dissertations, academic
Last Screening
Site Screening
Cancer Screening
Going Well
Violence
Biomedicine
screening
Genetic Screening
Eligibility Determination
general practice
Family Practice
County
Substance Screening
Trial Screening
mass screening
Human Cells, Tissues, and Cellular and Tissue-Based Products Screening
Screening Study
Burgundy Flavor
state medicine
spouse abuse

---
Nous contacter.
02/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.